To include your compound in the COVID-19 Resource Center, submit it here.

Celgene acquiring Juno for $9B

Celgene Corp. (NASDAQ:CELG) said it will acquire Juno Therapeutics Inc. (NASDAQ:JUNO) for $87 per share, or about $9 billion. The price is a 28% premium to Juno's close of $67.81 on Jan. 19, before the deal was announced, and a 91% premium to its closing price of $45.60 on Jan. 16, when rumors

Read the full 535 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers